Rafferty Asset Management LLC raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Get Rating) by 20.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 62,461 shares of the medical research company’s stock after purchasing an additional 10,585 shares during the quarter. Rafferty Asset Management LLC’s holdings in Amgen were worth $14,052,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also added to or reduced their stakes in the company. Jacobi Capital Management LLC lifted its holdings in shares of Amgen by 10.7% in the 3rd quarter. Jacobi Capital Management LLC now owns 12,212 shares of the medical research company’s stock worth $2,597,000 after acquiring an additional 1,185 shares during the last quarter. Boston Partners increased its position in Amgen by 57.1% during the 4th quarter. Boston Partners now owns 1,135,035 shares of the medical research company’s stock valued at $255,349,000 after purchasing an additional 412,337 shares during the period. Equitable Holdings Inc. increased its position in Amgen by 11.2% during the 3rd quarter. Equitable Holdings Inc. now owns 10,959 shares of the medical research company’s stock valued at $2,330,000 after purchasing an additional 1,102 shares during the period. Avantax Advisory Services Inc. increased its position in Amgen by 2.1% during the 4th quarter. Avantax Advisory Services Inc. now owns 30,188 shares of the medical research company’s stock valued at $6,793,000 after purchasing an additional 613 shares during the period. Finally, Peapack Gladstone Financial Corp grew its position in shares of Amgen by 1.1% in the 3rd quarter. Peapack Gladstone Financial Corp now owns 74,558 shares of the medical research company’s stock worth $15,855,000 after buying an additional 808 shares during the last quarter. Institutional investors and hedge funds own 79.01% of the company’s stock.
In related news, EVP Jonathan P. Graham sold 13,500 shares of the business’s stock in a transaction on Tuesday, May 10th. The shares were sold at an average price of $241.81, for a total value of $3,264,435.00. Following the completion of the sale, the executive vice president now directly owns 37,333 shares of the company’s stock, valued at $9,027,492.73. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 0.46% of the stock is owned by insiders.
Amgen (NASDAQ:AMGN – Get Rating) last posted its earnings results on Wednesday, April 27th. The medical research company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $4.22 by $0.03. Amgen had a net margin of 21.75% and a return on equity of 165.95%. The company had revenue of $6.24 billion for the quarter, compared to analysts’ expectations of $6.09 billion. During the same quarter in the prior year, the company posted $3.70 earnings per share. As a group, sell-side analysts predict that Amgen Inc. will post 17.49 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 8th. Investors of record on Tuesday, May 17th will be issued a $1.94 dividend. The ex-dividend date of this dividend is Monday, May 16th. This represents a $7.76 annualized dividend and a yield of 3.19%. Amgen’s dividend payout ratio (DPR) is 76.38%.
Several analysts have weighed in on AMGN shares. Mizuho boosted their target price on shares of Amgen from $202.00 to $208.00 in a research report on Tuesday. Morgan Stanley dropped their target price on shares of Amgen from $238.00 to $237.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 12th. Barclays boosted their target price on shares of Amgen from $233.00 to $236.00 and gave the stock an “equal weight” rating in a research report on Tuesday, April 12th. StockNews.com downgraded shares of Amgen from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 5th. Finally, Jefferies Financial Group boosted their target price on shares of Amgen from $266.00 to $280.00 and gave the stock a “buy” rating in a research report on Wednesday, February 9th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $240.40.
Amgen Profile (Get Rating)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
- Get a free copy of the StockNews.com research report on Amgen (AMGN)
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
- The S&P 500 Could Fall Another 28%
- Corning Stock is a Technology Value Play
- Wolverine Worldwide Is Ready To Rebound
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.